PRODUCTION OF CLINICAL GRADE DNA VECTORS EXPRESSING CO-STIMULATORY MOLECULES FOR ENHANCING THE EFFECT OF SPECIFIC ANTIGEN-PEPTIDE VACCINATION IN CANCER PATIENTS.

Notice Date

October 18, 2001

Contracting Office

NIH/TDCB, 6120 Executive Blvd., Suite 450, Rockville, MD 20852

ZIP Code

20852

E-Mail Address

Click here to send a message to the CRADA point of (FrisbieS@otd.nci.nih.gov)

Description

National Cancer Institute Technology Transfer Branch CRADA Opportunity Announcement Summary: The National Cancer Institute (NCI) is currently seeking a Collaborator for a Cooperative Research and Development Agreement (CRADA) to work with investigators in the Center for Cancer Research (CCR) to develop DNA vectors expressing co-stimulatory molecules for enhancing the effect of peptide vaccines. Proposed NCI Contribution: The NCI investigators have developed a new strategy to enhance the vaccination of patients with peptides. The NCI investigators would like to utilize this technology to treat patients with cancer. Accordingly, the NCI investigators will develop and conduct clinical trials to utilize these reagents in the treatment of cancer patients. Proposed CRADA Collaborator Contribution: The Collaborator will develop clinical grade DNA vectors expressing the specific co-stimulatory molecules. Proposed Joint Contribution: NCI and the Collaborator will jointly design a CRADA research plan and will jointly interpret the data generated under the research plan. Selection Criteria for Choosing the CRADA Collaborator May Include: 1. A demonstrated background and expertise in production of clinical grade DNA vectors. 2. A demonstrated record of success in the commercial development and production of products related to this area of technology. 3. The willingness to commit best effort and demonstrated resources to the research and development of the DNA vectors for clinical use. 5. The level of financial and staffing support the CRADA Collaborator will provide for CRADA-related activities. 6. The willingness to cooperate with the NCI in the timely publication of research results. 7. The agreement to be bound by the appropriate Department of Health and Human Services (DHHS) regulations relating to human subject research and to all Public Health Service (PHS) policies relating to the use and care of laboratory animals. 8. The willingness to accept the legal provisions and language of the CRADA. These provisions govern the distribution of future patent rights to CRADA inventions. Generally, the rights of ownership are retained by the organization that is the employer of the inventor with (1) the grant of a license for research and other Government purposes to the Government when the CRADA Collaborator's employee is the sole inventor, or (2) the grant of an option to elect an exclusive or nonexclusive license to the CRADA Collaborator when the Government employee is the sole inventor. Response Procedure: Interested parties should notify the Technology Transfer Branch of the NCI in writing of their interest in the CRADA collaboration no later than November 28, 2001. The written notice should briefly address the selection criteria listed above. Contact Information: CRADA Contact: Suzanne M. Frisbie, Ph.D. 6120 Executive Boulevard, Suite 450 Rockville, Maryland 20852 Phone: 301-496-0477; Fax: 301-402-2117 E-mail: FrisbieS@otd.nci.nih.gov

Web Link

Click here to view the standard NIH CRADA document. (http://ttb.nci.nih.gov/forms.html)

Record

Loren Data Corp. 20011022/SPMSC004.HTM (W-291 SN5109L5)